Related Experiment Video
Updated: May 1, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[An overview: new direct oral anticoagulants (DOAC)]
New oral anticoagulants offer alternatives for stroke prevention in atrial fibrillation. Physicians require experience with these direct-acting drugs, considering interactions and patient factors for effective real-world use.
Area of Science:
- Pharmacology
- Cardiology
- Internal Medicine
Context:
- Novel oral anticoagulants (NOACs) are increasingly used for stroke prevention in atrial fibrillation.
- These direct-acting agents represent a shift from traditional vitamin-K antagonists.
- Dabigatran (thrombin inhibitor) and rivaroxaban (factor X inhibitor) have significant clinical data.
Purpose:
- To highlight the clinical considerations for implementing new oral anticoagulants in real-world practice.
- To emphasize the need for physician experience with NOACs.
- To identify key areas requiring special attention for safe and effective NOAC use.
Summary:
- New oral anticoagulants (NOACs) are direct-acting agents for stroke prevention in atrial fibrillation, offering an alternative to vitamin-K antagonists.
- While large studies support their efficacy, real-world application requires physician experience.
- Key considerations include managing drug interactions, renal function, and peri-interventional bridging.
Impact:
- Facilitating the successful transition of NOACs from clinical trials to routine patient care.
- Improving patient outcomes by ensuring safe and effective use of novel anticoagulants.
- Guiding healthcare providers in optimizing anticoagulant therapy for stroke prevention.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antihypertensive Drugs: Direct Renin Inhibitors
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Venous Thrombosis III: Interprofessional Care

